About > Company
The Adial Vision
To build the world’s leading addiction-focused pharmaceutical company
Adial is focused on developing therapies for the treatment and prevention of addiction and related disorders. Our lead investigational drug candidate, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in patients with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Through its subsidiary, Purnovate, is also developing adenosine analogs for the treatment of pain, asthma, cancer, diabetes, and other disorders.
The Adial Story
Adial was founded on the ground-breaking work of Bankole A. Johnson, M.D., D.Sc. Dr. Johnson began his work in the 1990’s and, once the genome was unlocked, focused on understanding the genetics behind addiction. After animal studies, imaging studies, and early clinical work, he hypothesized that a serotonin-3 blocker might help people with certain genetics related to the serotonin system. After a Phase 2 study conducted by the University of Virginia at three sites in Virginia and one site in Texas, he met William Stilley and Adial Pharmaceuticals was founded in 2010 and began operations in 2011.
Licenses AD04 from the University of Virginia
USPTO grants 1st U.S. patent for AD04 for the treatment of Alcohol Use Disorder (AUD) in genetically targeted patients
Adial Pharmaceuticals listed on U.S. NASDAQ
ONWARD Phase 3
ADO4 Onward Phase 3 Trials begin
Adial acquires Purnovate, Inc. and its adenosine platform with potential to generate novel therapies, including a non-opioid pain program.
“The acquisition of Purnovate is transformative for Adial. Adial’s review of specific and proprietary adenosine analog compounds developed by Purnovate as non-opioid alternatives for the treatment of pain, appear promising and the addition of Purnovate’s fully operational laboratory and chemicals library, as well as its intellectual property, substantially increase the value of assets owned and controlled by Adial.”
ONWARD Phase 3 Trials completed
ONWARD Phase 3 Trial results announced